Tiger Global Management's 13F portfolio increased to $23.44B. Check out the notable increases, decreases, and new stakes of ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Eli Lilly shares rose nearly 1.6% on Wednesday morning to three-week highs after the company unveiled promising results from ...

With November coming to a close, while markets are focused on the future of artificial intelligence and the degree of ...

Global shares were mixed and the euro was steady on Wednesday as markets digested political turmoil in South Korea, where ...

Eli Lilly (LLY) stock is rising after the company said its weight-loss drug achieved better results than Wegovy ...

Eli Lilly's Zepbound has outperformed Novo Nordisk's Wegovy in a pivotal clinical trial, marking a significant milestone in ...

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...